Caris Life Sciences, Inc. (CAI) company profile
Close on Nov 17, 2026Market cap $5.63BP/E –Yield –
About Caris Life Sciences
Services-Medical Laboratories, SIC 8071
Caris is a precision medicine and biotechnology enterprise that develops and commercializes artificial intelligence-powered molecular profiling solutions focused primarily on oncology. Its offerings span the cancer care continuum, including early detection, minimal residual disease tracking, therapy selection, and treatment monitoring, as well as drug target discovery. The core product lines include the MI Profile platform for tissue-based whole exome and whole transcriptome sequencing, the Caris Assure platform for blood-based profiling, and the Precision Whole Genome platform. Caris serves clinical, academic, and biopharmaceutical markets, delivering molecular reports to treating oncologists while collaborating with biopharma companies and academic centers on biomarker research and therapeutic pipelines.
The company provides profiling services across major health systems, academic cancer institutions, and community settings, serving more than 6,000 ordering physicians in the United States. Its clinical solutions are available across U.S. states and Puerto Rico, and internationally via distributors and direct hospital contracts. In addition, Caris coordinates research with cancer centers worldwide through the Caris Precision Oncology Alliance. The provided text does not state the company's headquarters location or official website.
Summary of the business section of Caris Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Caris Life Sciences, Inc.
- Founded
- 2008
- Headquarters
- Irving, TX
- Address
- 750 W John Carpenter Freeway, Suite 800 75039
- Phone
- (866) 771-8946
- Website
- www.carislifesciences.com
- Employees
- 1,846, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Dallas, Texas
Stock & identifiers
- Ticker
- CAI
- Exchange
- Nasdaq
- IPO date
- Jun 20, 2025
- Shares outstanding
- 283M, Aug 3, 2026
- Public float
- $3.87B, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 2019410
- CUSIP
- 142152107
- ISIN
- US1421521071
- FIGI
- BBG00255V2N4
- Share class FIGI
- BBG00255V2P2
- LEI
- 549300LX5LO78M5VPY43
- EIN
- 85-2077369
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian J. Brille | See Remarks, Director | 1,130,303 |
| David D. Halbert | See Remarks, Director | 123,599,535 |
| John Russel Denton | See Remarks | 184,039 |
| David Baxley Spetzler | President | 1,302,083 |
| Luke Thomas Power | See Remarks | 153,771 |
| Laura I. Johansen | Director | 343,897 |
| T. Danny Phillips | Director | 133,060 |
| David Paul Fredrickson | Director | 31,813 |
| Peter M. Castleman | Director | 10,683,714 |
| Jeff L. Vacirca | Director | 62,863 |
| Jon Halbert | Director | 1,490,406 |
| Lloyd Minor | Director | 31,813 |
| Joseph E. Gilliam | Director | 29,321 |
| Jonathan Kenneth Charles Knowles | Director | 308,979 |
| George Poste | Director | 529,431 |
| Caris Halbert, L.P. | Director | 123,462,091 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| David Dean Halbert Chief Executive Officer | $764.92K | $3.26M | $15.40M | – | $925.77K | $20.35M | +804% |
| David Spetzler President | $611.93K | $703.73K | $2.78M | $7.47M | $14.00K | $11.58M | +854% |
| J. Russel Denton Senior Vice President, General Counsel and Secretary | $458.95K | $263.90K | $2.09M | $2.53M | $14.00K | $5.35M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 20, 2025
- Offer price
- $21.00
- Securities offered
- 23,529,412
- Gross proceeds
- $494.12M
- Exchange
- Nasdaq
- First trading day
- Jun 18, 2025
- First-day close
- $28.00+33.3%
- Lock-up ends (est.)
- Dec 15, 2025
“than 5% of our outstanding capital stock, and their respective affiliates will collectively beneficially own approximately 66.2% of our outstanding shares of common stock, in each case, based on the initial public offering price of $21.00 per share and assuming no exercise by the underwriters of their option to purchase additional shares of our common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 16, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 20, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 13, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?